Reviews and guidelines
Systematic reviews, meta-analyses and guidelines on MS and related diseases, linked to the research they cover.
1,997 reviews and guidelines
2,718 trial result papers linked to trials →2,718 trial result papers
Tiss A, Michaelson NM, Russo AW, Ramos-Torres KM, Sun Y, DaSilva NE, Noel JM, Liu F, Gong K, Huang SY, Popko B, Baker S, Klawiter EC, Brugarolas P. First evaluation in multiple sclerosis using PET tracer [18F]3F4AP demonstrates heterogeneous binding across lesions. Eur J Nucl Med Mol Imaging. 2026 Jan;53(2):1125-1138. doi: 10.1007/s00259-025-07454-1. Epub 2025 Aug 5.
Eur J Nucl Med Mol Imaging · 2026
Prosperini L, Tacchino A, Ruggieri S, Brichetto G, Podda J, Anastasi D, Cardini R, Corrini C, Quartuccio ME, Alcamisi I, Di Giovanni R, Gamberini G, Grange E, Pietrolongo E, Rispoli MG, Tomassini V, Cattaneo D, Solaro C. Home-based EXergames To impRovE cognitive function in MUltiple Sclerosis (EXTREMUS). J Neurol Neurosurg Psychiatry. 2026 Feb 13;97(3):217-228. doi: 10.1136/jnnp-2025-336609.
J Neurol Neurosurg Psychiatry · 2026
Bae M, Gell NM, Ramsey C, Kasser SL. Feasibility of home-based high-intensity balance training in persons with multiple sclerosis: A pretest-posttest study. Clin Rehabil. 2026 Jan;40(1):30-43. doi: 10.1177/02692155251384079. Epub 2025 Oct 17.
Clin Rehabil · 2026
Minen MT, George A, Bostic R, Fanning K, Bubu OM. The association between insomnia and migraine disability and quality of life: a secondary analysis of a randomized controlled trial. Pain Med. 2026 Apr 1;27(4):426-433. doi: 10.1093/pm/pnaf149.
Pain Med · 2026
Spain RI, Paz Soldan MM, Freedman MS, Repovic P, Solomon AJ, Rinker JR, Wallin MT, Haselkorn JK, Stuve O, Gross RH, Waslo CS, Hildebrand A, Morris CD, Mitchell J, Turner AP, Schwartz DL, Metz J, Rooney W. Lipoic Acid for Treatment of Progressive Multiple Sclerosis: A Phase 2 Randomized Clinical Trial. Neurology. 2026 Jan 13;106(1):e214454. doi: 10.1212/WNL.0000000000214454. Epub 2025 Dec 15.
Neurology · 2026
Cleland BT, Jeng B, Brown N, Motl RW, Madhavan S. Feasibility and efficacy of peak-velocity interval training vs. moderate-intensity walking training in people with multiple sclerosis with severe fatigue and walking impairment: A pilot randomized controlled trial. Mult Scler Relat Disord. 2026 Feb;106:106930. doi: 10.1016/j.msard.2025.106930. Epub 2025 Dec 12.
Mult Scler Relat Disord · 2026
Remotely-delivered exercise training program among older adults with multiple sclerosis: Feasibility results of a randomized controlled trial.
Contemp Clin Trials · 2026
Contribution of structural and functional MRI in predicting response to motor training in multiple sclerosis.
Mult Scler · 2026
Mukhtar S, Aljohani G, Bakkar M, Almutairi N, Mazi A, Alsweed L, Albadi M, Aldhabi R, Khan F. The effects of trunk rehabilitation on balance, gait, falls, and community mobility in patients with multiple sclerosis: A single-blind randomized controlled trial. Mult Scler Relat Disord. 2026 Feb;106:106929. doi: 10.1016/j.msard.2025.106929. Epub 2025 Dec 13.
Mult Scler Relat Disord · 2026
Calabresi PA, Giovannoni G, Hartung HP, Naismith RT, Fox RJ, Sormani MP, Arnold DL, Kappos L, Valis M, Newsome SD, Belkin MI, Bartholome E, Riester K, Javor A, Lyons J, Bradley DP, Fisher E, Tagge I, Naylor ML, Belachew S, Deykin A, Franchimont N, Zhu B, Cheng W. Safety and efficacy of opicinumab in participants with relapsing multiple sclerosis (AFFINITY Part 1): A randomized, controlled, phase 2
Mult Scler · 2026
Abdelgaied MY, Abdelgawad O, Rashad MH, Solayman MH, El-Tayebi HM. Efficacy and tolerability of metformin as an adjuvant therapy in patients with relapse-remitting multiple sclerosis receiving interferon Beta 1a: A randomized pilot trial. J Neuroimmunol. 2026 Mar;412:578852. doi: 10.1016/j.jneuroim.2025.578852. Epub 2025 Dec 31.
J Neuroimmunol · 2026
Exercise induces structural brain changes and elevates irisin levels and enhances functional performance in multiple sclerosis a pilot randomized study.
Sci Rep · 2026
Results of a pilot randomized controlled trial of a COM-B-based physical activity behavior-change intervention in people newly diagnosed with multiple sclerosis.
Mult Scler Relat Disord · 2026
Vascular Comorbidities and an Increased Comorbidity Score Are Associated With Disability and Disability Progression in Secondary Progressive Multiple Sclerosis.
Eur J Neurol · 2026
Dreijer N, Maffei LB, Veldman MP, Simmelink EK, Heersema DJ, Meilof JF, Zijdewind I. Transcutaneous electrical nerve stimulation improves walking in fatigued persons with multiple sclerosis: a randomized controlled trial. Ann Phys Rehabil Med. 2026 Apr;69(3):102081. doi: 10.1016/j.rehab.2025.102081. Epub 2026 Feb 11.
Ann Phys Rehabil Med · 2026
Cree BAC, Fox E, Hartung HP, Alvarez E, Qian P, Wray S, Robertson D, Selmaj K, Wynn D, Mok K, Rowland C, Bodhinathan K, Sportelli P, Miskin HP, Steinman L. Five Years of Ublituximab in Multiple Sclerosis: ULTIMATE I and II Open-Label Extension Study. JAMA Neurol. 2026 Apr 1;83(4):348-358. doi: 10.1001/jamaneurol.2026.0007.
JAMA Neurol · 2026
Miller A, Cohen JA, Karni A, Popper L, Bleich Kimelman N, Rubnov S, Danon U, Marom E, Boyko A, Zivadinov R, Berger JR, Bar-Or A, Kolb H. GA Depot, a long-acting glatiramer acetate, vs placebo in patients with relapsing multiple sclerosis: A randomized phase 3 clinical trial. Mult Scler. 2026 Feb;32(2):202-213. doi: 10.1177/13524585251405101. Epub 2026 Feb 18.
Mult Scler · 2026
Bejarano I, Jimenez-Jorge S, Lobo-Acosta MA, Alvarez-Lopez AI, Rosso-Fernandez CM, Lopez-Ruiz R, Eichau S, Ruiz-Pena JL, Geniz MA, Ampuero J, Ponce-Espana E, Merino-Bohorquez V, Camean M, Garcia-Sanchez MI, Izquierdo G, Guerrero JM, Romero-Gomez M, Lardone PJ, Carrillo-Vico A. Hepatic Safety of Adjunctive High-Dose Melatonin in Participants Receiving Ocrelizumab for Primary Progressive Multiple Sc
CNS Drugs · 2026
Tomezzoli A, Cassard B, Leblong E, Hayter J, Anne C, Bodet L, Pontonnier C. Are Isokinetic Torque-Angle Models Derived from Healthy Subjects Applicable to Patients with Upper-Limb Neurological Motor Impairment? Ann Biomed Eng. 2026 Jul;54(7):2066-2076. doi: 10.1007/s10439-026-04041-9. Epub 2026 Feb 22.
Ann Biomed Eng · 2026
Psychometric validation of PROMIS-Fatigue-MS-8a and MSIS-29v2 questionnaires in relapsing multiple sclerosis participants enrolled in a phase 2 trial of frexalimab.
Mult Scler Relat Disord · 2026
Randomized controlled trial of a remotely-delivered exercise training program in older adults with multiple sclerosis: Secondary effects on cognition, symptoms, and quality of life.
Mult Scler Relat Disord · 2026
A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Fenebrutinib and Effect on the QT/QTc Interval in Healthy Participants.
Clin Transl Sci · 2026
Bennett JL, Bhattacharyya S, Zabeti A, Levy M, de Seze J, Taney MJ, Parks B, Allen K, Akpoji U, Pittock SJ. Safety and efficacy of ravulizumab in patients with NMOSD previously treated with rituximab: A post hoc analysis of the CHAMPION-NMOSD trial. Mult Scler. 2026 Apr;32(4):396-408. doi: 10.1177/13524585261425076. Epub 2026 Mar 4.
Mult Scler · 2026
Karakas H, Ertekin O, Yavas I, Gozubatik-Celik RG, Kazdagli H, Seebacher B, Kahraman T. Effect of Telerehabilitation-Based Music Therapy and Motor Imagery on Pain, Autonomic Function, and Psychosocial Outcomes in People With Multiple Sclerosis: A Randomized Controlled Trial Protocol. Physiother Res Int. 2026 Apr;31(2):e70186. doi: 10.1002/pri.70186.
Physiother Res Int · 2026
Model-Informed Precision Dosing of Protein Kinase Inhibitors: Evaluation of Model-Averaging and Flattened Priors Methods.
Clin Pharmacokinet · 2026
Assembled by software from public sources.